Eisner Mark 4

What Happened

• Mark Eisner, EVP and Chief Medical Officer of Vir Biotechnology (VIR), sold a total of 3,505 shares in two transactions: 1,616 shares on 2026-02-24 at $9.53 each ($15,405) and 1,889 shares on 2026-02-25 at $9.82 each ($18,550), for combined proceeds of about $33,955. These were sales (disposals), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 1,616 shares @ $9.53 = $15,405 (Sale)
  • 2026-02-25: 1,889 shares @ $9.82 = $18,550 (Sale)
• Total shares sold: 3,505; total proceeds: ~$33,955.
• Shares owned after the transactions: not specified in the provided filing details.
• Footnotes from the filing:
  • F1: The Feb 24 sale represents an automatic/mandatory sale under a Rule 10b5‑1 arrangement to satisfy the issuer’s tax withholding obligations related to RSU vesting (not a discretionary trade).
  • F2: The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted May 19, 2025.
• Filing/timeliness: Form 4 filed 2026-02-26 following the Feb 24–25 transactions; this appears to be within the standard reporting window.

Context

• A Rule 10b5‑1 plan lets insiders sell shares according to a prearranged schedule and helps show the trades were planned, not based on inside information. Footnote F1 indicates at least one sale was automatic to cover tax withholding tied to RSU vesting. Such tax‑withholding sales are routine and do not necessarily signal the insider’s view on the company’s prospects.